A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Inclusion Criteria: * Active AMD with Subfoveal CNV (classic and/or occult CNV) * CNV lesion thickness \>/= 250um by OCT assessment * Visual acuity in study eye of \</= 20/100 but not worse than 20/800 * Not eligible for or refused standard treatment Exclusion Criteria: * Females of childbearing potential * Other causes of CNV including pathologic myopia, the ocular histoplasmosis syndrome, angioid streaks, choroidal rupture and multifocal choroiditis * Any intraocular surgery or treatment of AMD with Visudyne within 3 months of study entry * CNV lesion \>/= 12 MPS disc area